- Home
- SKYE vs PSTL Comparison
SKYE vs PSTL Comparison
Compare SKYE & PSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- PSTL
- Stock Information
- Founded
- SKYE 2012
- PSTL 2018
- Country
- SKYE United States
- PSTL United States
- Employees
- SKYE N/A
- PSTL N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- PSTL Real Estate Investment Trusts
- Sector
- SKYE Health Care
- PSTL Real Estate
- Exchange
- SKYE Nasdaq
- PSTL Nasdaq
- Market Cap
- SKYE 108.3M
- PSTL 320.0M
- IPO Year
- SKYE N/A
- PSTL 2019
- Fundamental
- Price
- SKYE $4.94
- PSTL $14.62
- Analyst Decision
- SKYE Buy
- PSTL Buy
- Analyst Count
- SKYE 6
- PSTL 2
- Target Price
- SKYE $18.67
- PSTL $15.75
- AVG Volume (30 Days)
- SKYE 308.0K
- PSTL 67.9K
- Earning Date
- SKYE 11-09-2024
- PSTL 11-01-2024
- Dividend Yield
- SKYE N/A
- PSTL 6.58%
- EPS Growth
- SKYE N/A
- PSTL N/A
- EPS
- SKYE N/A
- PSTL 0.09
- Revenue
- SKYE N/A
- PSTL $68,445,000.00
- Revenue This Year
- SKYE N/A
- PSTL N/A
- Revenue Next Year
- SKYE N/A
- PSTL $12.21
- P/E Ratio
- SKYE N/A
- PSTL $167.49
- Revenue Growth
- SKYE N/A
- PSTL 15.46
- 52 Week Low
- SKYE $1.44
- PSTL $13.00
- 52 Week High
- SKYE $19.41
- PSTL $15.15
- Technical
- Relative Strength Index (RSI)
- SKYE 58.26
- PSTL 55.79
- Support Level
- SKYE $4.01
- PSTL $14.46
- Resistance Level
- SKYE $5.48
- PSTL $14.73
- Average True Range (ATR)
- SKYE 0.46
- PSTL 0.19
- MACD
- SKYE 0.19
- PSTL 0.04
- Stochastic Oscillator
- SKYE 73.79
- PSTL 84.87
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.